Equities analysts expect Marinus Pharmaceuticals Inc (NASDAQ:MRNS) to post earnings per share (EPS) of ($0.25) for the current quarter, Zacks reports. Zero analysts have made estimates for Marinus Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.23). Marinus Pharmaceuticals posted earnings per share of ($0.24) in the same quarter last year, which would indicate a negative year over year growth rate of 4.2%. The firm is scheduled to announce its next earnings report on Monday, March 9th.
On average, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.86). For the next fiscal year, analysts forecast that the company will report earnings of ($0.74) per share, with EPS estimates ranging from ($1.00) to ($0.53). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Marinus Pharmaceuticals.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02).
Institutional investors and hedge funds have recently modified their holdings of the company. Northern Trust Corp lifted its stake in shares of Marinus Pharmaceuticals by 1.9% during the second quarter. Northern Trust Corp now owns 548,467 shares of the biopharmaceutical company’s stock valued at $2,276,000 after acquiring an additional 10,204 shares during the period. Morgan Stanley lifted its stake in shares of Marinus Pharmaceuticals by 1,679.6% during the second quarter. Morgan Stanley now owns 187,889 shares of the biopharmaceutical company’s stock valued at $780,000 after acquiring an additional 177,331 shares during the period. Vanguard Group Inc. lifted its stake in shares of Marinus Pharmaceuticals by 4.7% during the second quarter. Vanguard Group Inc. now owns 2,587,314 shares of the biopharmaceutical company’s stock valued at $10,737,000 after acquiring an additional 115,294 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Marinus Pharmaceuticals by 32.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 126,761 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 31,260 shares during the period. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of Marinus Pharmaceuticals during the second quarter valued at $76,000. 57.99% of the stock is currently owned by institutional investors and hedge funds.
Marinus Pharmaceuticals stock traded down $0.02 on Monday, reaching $1.30. The company’s stock had a trading volume of 463,700 shares, compared to its average volume of 940,554. The company has a market cap of $71.11 million, a price-to-earnings ratio of -1.44 and a beta of 2.87. The business’s fifty day moving average price is $1.21 and its 200 day moving average price is $2.32. Marinus Pharmaceuticals has a twelve month low of $0.77 and a twelve month high of $6.00.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Further Reading: What is the cash asset ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.